Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michele Wible"'
Autor:
Michele Wible, Yongjie Zhao, Ping Yan, Margaret Tawadrous, Ping Li, Yingyuan Zhang, Xiajun Xu, Gang Chen, Lihong Xu, Yijian Chen, Demei Zhu, M. Anne Hickman
Publikováno v:
Therapeutics and Clinical Risk Management
Yijian Chen,1,2,* Demei Zhu,1,2,* Yingyuan Zhang,1,2 Yongjie Zhao,3 Gang Chen,4 Ping Li,5 Lihong Xu,6 Ping Yan,6 M Anne Hickman,7 Xiajun Xu,6 Margaret Tawadrous,7 Michele Wible7 1Institute of Antibiotics, Huashan Hospital Fudan University, Shanghai,
Publikováno v:
Infection and Drug Resistance. 10:401-417
Background Acinetobacter infections, especially multidrug-resistant (MDR) Acinetobacter infections, are a global health problem. This study aimed to describe clinical outcomes in patients with confirmed Acinetobacter spp. isolates who were treated wi
Autor:
Vera Frajzyngier, Scott T. Rottinghaus, Alvaro Quintana, Anne Hickman, Matteo Bassetti, Philippe Montravers, Michele Wible, Nathalie Baillon-Plot, Christian Eckmann, Hal Tucker, Rebecca Lundin
Publikováno v:
Pharmaceutical Medicine. 31:89-99
Risk minimization measures (RMM) were implemented from February 2011 in the European Union to address risks of superinfection, off-label use and lack of efficacy associated with tigecycline. The objective of this study was to evaluate RMM effectivene
Autor:
Nathalie Baillon-Plot, M. Anne Hickman, Joan M. Korth-Bradley, Margaret Tawadrous, Mike Sharland, Humberto Díaz-Ponce, Michele Wible, Hal Tucker, Keith A. Rodvold, Susan Raber
Publikováno v:
The Pediatric infectious disease journal. 38(7)
BACKGROUND: The need for antimicrobial therapies effective against multidrug resistant organisms for children remains unmet. Tigecycline shows antibacterial activity across a broad spectrum of bacteria and is approved for treating complicated skin an
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives To examine the incidence of pancreatitis among subjects enrolled in the tigecycline clinical trial programme, summarize cases and examine concomitant use of other pancreatitis-causing medications. Methods Subject data from Phase 3 and 4 co
Publikováno v:
BMC Infectious Diseases
Background The presence of diabetes mellitus increases the risk of several severe infections, but data on its effect on treatment outcomes in patients with nosocomial pneumonia (NP) caused by methicillin-resistant Staphylococcus aureus (MRSA) are lim
Autor:
Beth P. Goldstein, Thomas J. Walsh, Johann Viljoen, Michele Wible, Ahmed E. Simjee, Timothy Henkel, David S. Krause, Christo van Rensburg
Publikováno v:
Clinical Infectious Diseases. 39:770-775
Anidulafungin is a novel antifungal agent of the echinocandin class. This randomized, double-blind, double-dummy study compared the efficacy and safety of intravenous anidulafungin to that of oral fluconazole in 601 patients with endoscopically and m
Autor:
Michael J. Dowzicky, Paul C. McGovern, Alvaro Quintana, Michele Wible, Douglas J. Biedenbach, Meredith Hackel, Samuel K. Bouchillon
Publikováno v:
Journal of Global Antimicrobial Resistance. 3:311-312
Table 2. In vitro activity of tigecycline against molecularly characterized MDR isolates collected from tigecycline phase III cSSSI and cIAI clinical trials and the TEST global surveillance program; frequency distribution (N) and cumulative percent i
Publikováno v:
Diagnostic microbiology and infectious disease. 79(2)
Given increasing resistance, therapeutic options to treat MRSA soft tissue infections should be evaluated. This pooled analysis evaluated data from subjects enrolled in 6 tigecycline clinical trials with documented MRSA complicated skin and skin stru
Autor:
David S. Krause, Peter G. Pappas, Thomas J. Walsh, Coleman Rotstein, Robert F. Betts, Stanley W. Chapman, Beth P. Goldstein, Michele Wible, Daniel H. Kett, Jennifer Schranz, Annette C. Reboli, Deepali Kumar
Publikováno v:
The New England journal of medicine. 356(24)
Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.Adults with invasive candidiasis were